期刊文献+

EGFR突变或ALK重排野生型肺腺癌术后转化为神经内分泌癌1例

下载PDF
导出
摘要 患者男性,71岁,吸烟史30年,因咳嗽、咳痰7d余,2016年11月29日就诊于我院。胸部CT示:右肺上叶尖段多毛刺结节。肿瘤标记物:CYFRA21-1测定4.09ng/ml,NSE、CEA、CA-153、CA-199、AFP、CA72-4Z正常范围。于2016年12月14日行肺部结节穿刺病理(图1,见插一)示:肺间质纤维化,局灶见少量异型增生的腺体,结合免疫组化考虑腺癌。免疫组化结果:CK7(+),Ki67(10%+),Napsina(+),TTF-1(+),P40(-),CEA(+),P53(+),CK2(-)。基因检测示:EGFR基因未检测到18、19、20、21外显子上的突变。
出处 《中日友好医院学报》 2019年第5期313-314,I0001,共3页 Journal of China-Japan Friendship Hospital
  • 相关文献

参考文献2

二级参考文献29

  • 1Ferlay J, Shin HR, Bray F, et al. Estimates of wordwide burden of cancerin 2008: GLOBOCAN 2008. IntJ Cancer, 2010, 127(12): 2893-2917.
  • 2Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000, 19(13): 3159-3167.
  • 3Engelman JA, Jiinne PA. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med, 2005, 26(3 ): 314-322.
  • 4Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Y EnglJ Med, 2009, 361(10): 947-957.
  • 5Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
  • 6Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-ceU lung cancer (NSCLC). Ann Oncol, 2013, 24(6): 1615-1622.
  • 7Wood DE. National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening. Tnorac Surg Clin, 2015, 25(2): 185-197.
  • 8Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Meal, 2011, 3(75): 75ra26.
  • 9Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet, 2012, 44(10): 1111-1116.
  • 10Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR- mutant lung cancers. Clin Cancer Res, 2013, 19(8): 2240-2247.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部